Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: An exploratory analysis of the outcomes of elderly patients in the RECORD-1 trial

European Urology

Volumn 61, Issue 4, 2012, Pages 826-833

  Porta, Camillo ^a   Calvo, Emiliano ^b   Climent, Miguel A ^c   Vaishampayan, Ulka ^d   Osanto, Susanne ^e   Ravaud, Alain ^f   Bracarda, Sergio ^g   Hutson, Thomas E ^h   Escudier, Bernard ⁱ   Grünwald, Viktor ^j   Kim, Dennis ^k   Panneerselvam, Ashok ^k   Anak, Oezlem ^k   Motzer, Robert J ^l  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Hospital Madrid Norte Sanchinarro   (Spain)

^c INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^d KARMANOS CANCER INSTITUTE   (United States)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f HÔPITAL SAINT ANDRÉ   (France)

^g IRCCS POLICLINICO SAN DONATO   (Italy)

^h BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j HANNOVER MEDICAL SCHOOL   (Germany)

^k NOVARTIS PHARMA AG   (Switzerland)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

Adverse events; Kidney cancer; mTOR inhibitor; Pneumonitis

Indexed keywords

EVEROLIMUS; PLACEBO;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSGEUSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEVER; GLUCOSE BLOOD LEVEL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INFECTION; KAPLAN MEIER METHOD; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; LIMB PAIN; LOG RANK TEST; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; STOMATITIS; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; TUMOR VOLUME; VOMITING;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; EUROPE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; MULTICENTER STUDIES AS TOPIC; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; UNITED STATES;

EID: 84862777361     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.12.057     Document Type: Article

References (15)

1. M. Aron, M.M. Nguyen, R.J. Stein, and I.S. Gill Impact of gender in renal cell carcinoma: an analysis of the SEER database Eur Urol 54 2008 133 142
2. J.W. Coebergh, M.L. Janssen-Heijnen, and P.P. Razenberg Prevalence of co-morbidity in newly diagnosed patients with cancer: a population-based study Crit Rev Oncol Hematol 27 1998 97 100 (Pubitemid 28179683)
3. L. Repetto, and D. Comandini Cancer in the elderly: assessing patients for fitness Crit Rev Oncol Hematol 35 2000 155 160
4. L. Repetto, A. Venturino, and M. Vercelli Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions Cancer 82 1998 760 765 (Pubitemid 28090289)
5. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
6. R.J. Motzer, B. Escudier, and S. Oudard Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
7. A.A. van der Veldt, E. Boven, and H.H. Helgason Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer Br J Cancer 99 2008 259 265
8. T. Eisen, S. Oudard, and C. Szczylik Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial J Natl Cancer Inst 100 2008 1454 1463
9. Escudier BJ, Ravaud A, Bracarda S, et al. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-a2a (IFN) in subgroups of patients (pts) with metastatic renal cell carcinoma (mRCC). Paper presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; February 14-16, 2008; San Francisco, CA, USA.
10. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124 (Pubitemid 46089672)
11. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
12. R.M. Bukowski, W.M. Stadler, and R.A. Figlin Safety and efficacy of sorafenib in elderly patients >65 years: a subset analysis from the Advanced Renal Carcinoma Sorafenib (ARCCS) expanded access program in North America [abstract 5045] J Clin Oncol 26 2008 (Suppl)
13. B.I. Rini, S. Halabi, and J.E. Rosenberg Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol 28 2010 2137 2143
14. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281 (Pubitemid 46849157)
15. J.P. Dutcher, N. Szczylik, and N. Tannir Correlation of survival with tumor histology, age and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon-alpha [abstract 5033] J Clin Oncol 25 2007 18S